Physician profile
Molly E Schug
NPI 1023336229
$1,634.99
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187 · 2020: $412 · 2021: $693 · 2022: $281 · 2023: $41.20 · 2024: $20.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $62.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $62.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $271.05 | 2019-2024 | Bexsero, Shingrix, Arexvy |
| Lilly USA, LLC | $215.77 | 2019-2022 | |
| Amarin Pharma, INC. | $178.80 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.25 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $109.78 | 2021 | |
| Novo Nordisk INC | $108.33 | 2019-2021 | |
| Pfizer INC. | $104.86 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $85.09 | 2022 | |
| Eisai INC. | $65.48 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $58.33 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $48.69 | 2019-2020 | |
| Seqirus USA INC | $39.53 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $35.92 | 2021 | |
| Dermira, INC. | $28.73 | 2020 | |
| Sanofi-Aventis U.S. LLC | $19.87 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $19.80 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.76 | 2021 | |
| Bausch Health US, LLC | $18.85 | 2021 | |
| Amgen INC. | $17.11 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.74 | 2022 | |
| Bioverativ Therapeutics INC. | $14.32 | 2019 | |
| Abbott Laboratories | $11.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Schug listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.